| Q24606651 | 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease |
| Q34760606 | Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. |
| Q92106898 | Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications |
| Q26781451 | Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy |
| Q36000325 | Antibodies as defensive enzymes |
| Q36825498 | Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies |
| Q37831912 | Antibody-based therapy in Alzheimer's disease |
| Q24646892 | Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis |
| Q34413715 | Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults |
| Q26740418 | Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications |
| Q40597257 | Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development |
| Q37926164 | Autoimmune and inflammatory mechanisms of CNS damage |
| Q35753932 | Autoreactive‐Aβ antibodies promote APP β‐secretase processing |
| Q38881198 | Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment |
| Q91236273 | B cells in autoimmune and neurodegenerative central nervous system diseases |
| Q59811749 | Bee venom phospholipase A2 ameliorates Alzheimer's disease pathology in Aβ vaccination treatment without inducing neuro-inflammation in a 3xTg-AD mouse model |
| Q35541293 | Beta-amyloid auto-antibodies are reduced in Alzheimer's disease |
| Q33791646 | Biomarkers in Alzheimer's disease: past, present and future |
| Q30651551 | Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease |
| Q37881948 | Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential |
| Q37688886 | Can Alzheimer disease be prevented by amyloid-beta immunotherapy? |
| Q33689076 | Can peripheral leukocytes be used as Alzheimer's disease biomarkers? |
| Q36724775 | Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease |
| Q34345602 | Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications |
| Q57779647 | Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer's Disease |
| Q37238681 | Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease |
| Q37626126 | Clinical applications of intravenous immunoglobulins in neurology |
| Q38206711 | Clinical trials of intravenous immunoglobulin for Alzheimer's disease |
| Q33625476 | Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study |
| Q34815916 | Do age-associated changes in 'physiologic' autoantibodies contribute to infection, atherosclerosis, and Alzheimer's disease? |
| Q51704620 | Donepezil modulates the endogenous immune response: implications for Alzheimer's disease |
| Q35184148 | ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects |
| Q36894417 | Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes |
| Q90050705 | Encoding the Sequence of Specific Autoantibodies Against beta-Amyloid and alpha-Synuclein in Neurodegenerative Diseases |
| Q58696119 | Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein |
| Q37287652 | Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry |
| Q41975386 | Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity |
| Q34419295 | Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease |
| Q24630334 | Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening |
| Q24599108 | Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease |
| Q33573668 | Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide |
| Q38208226 | Immunomodulation and AD--down but not out. |
| Q73631902 | Immunotherapy for Alzheimer's disease |
| Q59824026 | Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies |
| Q37044228 | Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease. |
| Q37024947 | Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients |
| Q53299775 | Innovative treatment approaches for Alzheimer's disease. Immunotherapy |
| Q27001177 | Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms |
| Q22241424 | Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease |
| Q48397446 | Intravenous immunoglobulin for Alzheimer's disease |
| Q97570188 | Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations |
| Q37179956 | Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial |
| Q37544756 | Mechanism-based treatments for Alzheimer's disease |
| Q26752508 | Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged |
| Q89566145 | Naturally Occurring Antibodies to Tau Exists in Human Blood and Are Not Changed in Alzheimer's Disease |
| Q38035776 | Naturally Occurring Autoantibodies Against β-Amyloid |
| Q51012796 | Naturally Occurring Autoantibodies against β-Amyloid: Investigating Their Role in Transgenic Animal andIn VitroModels of Alzheimer's Disease |
| Q30489052 | Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. |
| Q48585657 | Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD. |
| Q42021752 | Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? |
| Q38020957 | Pathogenic and physiological autoantibodies in the central nervous system |
| Q37068847 | Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease |
| Q89964006 | Peripheral Routes to Neurodegeneration: Passing Through the Blood-Brain Barrier |
| Q57039635 | Peripheral immune system in aging and Alzheimer's disease |
| Q35852763 | Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease |
| Q37504001 | Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics |
| Q92875343 | Potential Fluid Biomarkers for the Diagnosis of Mild Cognitive Impairment |
| Q38053449 | Potential sources of interference on Abeta immunoassays in biological samples |
| Q41597801 | Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders |
| Q37438261 | Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy |
| Q27317159 | Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cells |
| Q35047977 | Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease |
| Q37954456 | Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications |
| Q36902286 | Systemic and acquired immune responses in Alzheimer's disease |
| Q24804900 | The immunotherapy of Alzheimer's disease |
| Q37862785 | Therapeutic applications of antibodies in non-infectious neurodegenerative diseases |
| Q38124622 | Therapeutics of Alzheimer's disease: Past, present and future |